Search research articles
Contact Us
Filters
Showing results (1-10 of 51) with videos related to
Page
of 6
Sort By:
Journal of Virology
|
May 12, 2025
Early short-course treatment fails to prevent disease or relapse upon discontinuance of treatment in infections in addition to COVID-19
Arthur M Friedlander
The New England Journal of Medicine
|
June 4, 2015
Management of potential bioterrorism-related conditions
Arthur M Friedlander
JAMA
|
July 2, 2002
Diagnosis and treatment of cutaneous anthrax
Arthur M Friedlander
Vaccine
|
October 20, 2009
Advances in the development of next-generation anthrax vaccines
Arthur M Friedlander, Stephen F Little
Human Vaccines & Immunotherapeutics
|
August 3, 2012
Military vaccines in today's environment
Connie S Schmaljohn, Leonard A Smith, Arthur M Friedlander
Journal of Visualized Experiments : Jove
|
June 9, 2020
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Jennifer Chua, Donald J Chabot, Tammy Putmon-Taylor, et al.
Biochemistry
|
October 22, 2014
A reaction path study of the catalysis and inhibition of the Bacillus anthracis CapD γ-glutamyl transpeptidase
Ilja V Khavrutskii, Patricia M Legler, Arthur M Friedlander, et al.
Antimicrobial Agents and Chemotherapy
|
December 28, 2007
Treatment of experimental anthrax with recombinant capsule depolymerase
Angelo Scorpio, Steven A Tobery, Wilson J Ribot, et al.
FEMS Microbiology Letters
|
June 13, 2017
Green tea and epigallocatechin-3-gallate are bactericidal against Bacillus anthracis
Shane D Falcinelli, Maggie C Shi, Arthur M Friedlander, et al.
Microbial Pathogenesis
|
September 8, 2004
The NheA component of the non-hemolytic enterotoxin of Bacillus cereus is produced by Bacillus anthracis but is not required for virulence
Itai Mendelson, Steve Tobery, Angelo Scorpio, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 51) with videos related to
Sort By:
Page
of 6
Journal of Virology
|
May 12, 2025
Early short-course treatment fails to prevent disease or relapse upon discontinuance of treatment in infections in addition to COVID-19
Arthur M Friedlander
The New England Journal of Medicine
|
June 4, 2015
Management of potential bioterrorism-related conditions
Arthur M Friedlander
JAMA
|
July 2, 2002
Diagnosis and treatment of cutaneous anthrax
Arthur M Friedlander
Vaccine
|
October 20, 2009
Advances in the development of next-generation anthrax vaccines
Arthur M Friedlander, Stephen F Little
Human Vaccines & Immunotherapeutics
|
August 3, 2012
Military vaccines in today's environment
Connie S Schmaljohn, Leonard A Smith, Arthur M Friedlander
Journal of Visualized Experiments : Jove
|
June 9, 2020
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Jennifer Chua, Donald J Chabot, Tammy Putmon-Taylor, et al.
Biochemistry
|
October 22, 2014
A reaction path study of the catalysis and inhibition of the Bacillus anthracis CapD γ-glutamyl transpeptidase
Ilja V Khavrutskii, Patricia M Legler, Arthur M Friedlander, et al.
Antimicrobial Agents and Chemotherapy
|
December 28, 2007
Treatment of experimental anthrax with recombinant capsule depolymerase
Angelo Scorpio, Steven A Tobery, Wilson J Ribot, et al.
FEMS Microbiology Letters
|
June 13, 2017
Green tea and epigallocatechin-3-gallate are bactericidal against Bacillus anthracis
Shane D Falcinelli, Maggie C Shi, Arthur M Friedlander, et al.
Microbial Pathogenesis
|
September 8, 2004
The NheA component of the non-hemolytic enterotoxin of Bacillus cereus is produced by Bacillus anthracis but is not required for virulence
Itai Mendelson, Steve Tobery, Angelo Scorpio, et al.
Page
of 6